medicine-news-1/gene-findings-revealing-reasons-for-neuroblastoma-risk-49275-2/;+health+history;+medical+history.html

[0] Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced [0] Caliper Life Sciences Launches Living Image(R) 4.0 Software [0] Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators [0] Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities

Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3 Van Andel Institute Cuts Ribbon on $178 Million Expansion 2 Van Andel Institute Cuts Ribbon on $178 Million Expansion 3 Van Andel Institute Cuts Ribbon on $178 Million Expansion 4 AEterna Zentaris Receives US 245 5 Million from Institutional Investors 14577 1 AEterna Zentaris Receives US 245 5 Million from Institutional Investors 14577 2 AEterna Zentaris Receives US 245 5 Million from Institutional Investors 14577 3 Gauze based NPWT Capable of Achieving Same Treatment Goals as Foam based NPWT 5665 1 Gauze based NPWT Capable of Achieving Same Treatment Goals as Foam based NPWT 5665 2 Gauze based NPWT Capable of Achieving Same Treatment Goals as Foam based NPWT 5665 3 Gauze based NPWT Capable of Achieving Same Treatment Goals as Foam based NPWT 5665 4 Governor Rendell Says Hundreds of Jobs Coming to York County as Medical Device Manufacturer Prepares to Expand 5662 1 Governor Rendell Says Hundreds of Jobs Coming to York County as Medical Device Manufacturer Prepares to Expand 5662 2 Governor Rendell Says Hundreds of Jobs Coming to York County as Medical Device Manufacturer Prepares to Expand 5662 3

[0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program [0] Van Andel Institute Cuts Ribbon on $178 Million Expansion